2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12D.05 Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups

P3.12D.05 Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups

Back to course

Pdf Summary

This study investigates the efficacy and safety of a combination treatment involving furmonertinib and icotinib, targeting patients with EGFR-mutated non-small cell lung cancer (NSCLC) characterized by L858R mutation or central nervous system (CNS) metastases. The trial is a single-arm, open-label, phase II study (ChiCTR2200060151) conducted by researchers from the Affiliated Hospital of Guangdong Medical University, China.<br /><br />All 45 participating patients had treatment-emergent adverse events (TEAEs), with 13.3% experiencing grade 3 TEAEs. The most common TEAEs included rash and diarrhea, among others. No dose reductions or treatment discontinuations were due to TEAEs. <br /><br />Efficacy results demonstrated a high systemic objective response rate (ORR) of 93.3% and a disease control rate (DCR) of 100% among all patients, indicating the efficacy of this treatment combination. For patients with L858R mutations, the ORR was 95.5%, with a median progression-free survival (PFS) of 22.5 months. Similarly, patients with CNS metastases showed an intracranial ORR of 94.1% and a systemic PFS of 25.6 months.<br /><br />The study revealed that furmonertinib plus icotinib was effective as a first-line treatment for patients with specific EGFR mutations or CNS metastases. The combination treatment was generally well-tolerated, with no new safety concerns arising. As the study is ongoing, further analyses will explore long-term treatment outcomes. The trial was supported by Shanghai Allist Pharmaceuticals Co., Ltd.<br /><br />In conclusion, furmonertinib plus icotinib appears promising as a treatment for EGFR-mutated NSCLC, especially in patients with poor prognoses due to L858R mutations or CNS metastases, with encouraging results on PFS and safety profiles.

Asset Subtitle

Hualin Chen

Meta Tag

Speaker Hualin Chen

Topic Metastatic NSCLC – Targeted Therapy

Keywords

furmonertinib

icotinib

EGFR-mutated NSCLC

L858R mutation

CNS metastases

phase II study

objective response rate

progression-free survival

treatment-emergent adverse events

Shanghai Allist Pharmaceuticals